Stories
Claroid Pharmaceuticals Files for IPO to Fund New Manufacturing Facility
N
News18•23-09-2026, 18:15
Claroid Pharmaceuticals Files for IPO to Fund New Manufacturing Facility
- •Claroid Pharmaceuticals has filed draft papers with Sebi for an IPO comprising a fresh issue of up to 74.50 lakh equity shares and an offer for sale of up to 51.50 lakh shares.
- •The net proceeds from the fresh issue will fund a new manufacturing facility in Ahmedabad, estimated to cost Rs 167.97 crore, for injectables, ampoules, vials, dry powder, pre-filled syringes, and eye-drop products.
- •The company currently operates a manufacturing facility at Pirana, Ahmedabad, producing tablets, capsules, and ointments, and has developed 129 pharmaceutical formulations across various therapeutic segments.
- •Claroid Pharmaceuticals has an export presence in Nigeria, Tanzania, Kenya, Myanmar, Zanzibar, and Botswana, with Nigeria being its largest export destination.
- •The company's revenue from operations surged to Rs 169.72 crore in FY26 from Rs 62.98 crore in FY24, achieving a compound annual growth rate (CAGR) of 64.13 percent.
Key Questions Answered
Claroid Pharmaceuticals' proposed initial public offering includes a fresh issue of up to 74.50 lakh equity shares and an offer for sale of up to 51.50 lakh shares, aggregating to a total of 1.26 crore equity shares according to its draft red herring prospectus.
The company plans to use the net proceeds from the fresh issue to fund capital expenditure for building a brand new manufacturing facility on its existing land in Ahmedabad.
The proposed facility will have an estimated cost of around Rs 167.97 crore and an installed capacity of 15 lakh units per month to manufacture injectables, ampoules, vials, dry powder, pre-filled syringes, and eye-drop products.
